NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 21/100

NeuBase Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 19, 2021 / 03:30PM GMT
Release Date Price: $100.2 (-3.84%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Hi. Welcome back, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets. We're really glad to have our next presenting company, NeuBase Therapeutics, represented by their CEO, Dietrich Stephan. Dietrich, thanks so much for joining us.

Dietrich A. Stephan
NeuBase Therapeutics, Inc. - Founder, President, CEO & Chairman

Hi, Brian, thanks for having us.

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Our pleasure.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So maybe just to kick things off for those who are newer to the NeuBase story. Can you walk us through the main advantages of the PNA technology approach that you guys -- that forms the foundation of the company when it comes to drug development. And maybe also touch upon why PNAs

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot